Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
Rhea-AI Summary
Syndax Pharmaceuticals (Nasdaq: SNDX) announced that CEO Michael A. Metzger will participate in a fireside chat at the 2026 Guggenheim Emerging Outlook: Biotech Summit on Thursday, February 12, 2026 at 12:30 p.m. ET.
A live webcast and limited-time replay will be available in the company Investor section at www.syndax.com.
Positive
- None.
Negative
- None.
News Market Reaction – SNDX
In the Feb 5 session, SNDX declined 1.37%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Preliminary 2025 results | Positive | -1.3% | Unaudited 4Q25 and 2025 revenues and cash position ahead of JP Morgan talk. |
| Jan 07 | Access program expansion | Positive | +8.7% | Multi-regional managed access program to broaden Revuforj availability outside U.S. |
| Jan 05 | JP Morgan presentation | Neutral | -5.1% | Announcement of CEO presentation at 44th Annual J.P. Morgan Healthcare Conference. |
| Dec 12 | Award and approvals | Positive | -0.2% | Revuforj named Best New Drug following two FDA approvals in acute leukemias. |
| Dec 08 | Clinical data update | Positive | -1.7% | Multiple Revuforj abstracts at ASH 2025 with high ORR, CR, and MRD negativity. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows several positive fundamental and clinical updates followed by flat-to-negative next-day moves, while one access-expansion announcement saw a strong positive reaction.
Over the past few months, Syndax has reported multiple value-defining milestones. On Dec 8, 2025 it highlighted strong Revuforj data at ASH 2025, followed by a Scrip Award for Best New Drug on Dec 12, 2025. A JP Morgan conference presentation was announced on Jan 5, 2026, then on Jan 7 the company expanded Revuforj access via a multi-regional managed access program. On Jan 12, preliminary 4Q25 and full-year 2025 revenue and cash figures were disclosed ahead of its conference presentation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 2026 Guggenheim Emerging Outlook: Biotech Summit on Thursday, February 12, 2026, at 12:30 p.m. ET.
A live webcast of the fireside chat will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
